RxDoctor Payments Data

Stephen Ellis, MD

Cardiovascular Disease · Cleveland, OHNPI 1679667208

Payments from drug & device makers

$126,441in general payments, 2019–2025

Across 113 payments — averaging $1118.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$72K
  • Medtronic$24K
  • Biotronik Inc.$13K
  • Abbott$11K
  • Boston Scientific$6K
  • Impulse Dynamics (USA) Inc.$103
  • plus $94 from 4 others

What the payments were for

  • Consulting fees$28,37558%
  • Speaking & faculty fees$9,87520%
  • Travel & lodging$6,86014%
  • Food & beverage$3,5747%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,441 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$85,326
Medicare patients
314
Services billed
660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$66,058
Repatha SureclickEvolocumab61$65,282
EntrestoSacubitril/Valsartan48$60,402
JardianceEmpagliflozin37$23,726
BrilintaTicagrelor13$12,494
Praluent PenAlirocumab12$5,790
ClopidogrelClopidogrel Bisulfate336$3,744
Metoprolol Succinate194$3,275
Atorvastatin Calcium303$2,439
Ranolazine ErRanolazine22$2,344
Isosorbide Mononitrate ErIsosorbide Mononitrate115$1,871
Rosuvastatin Calcium117$1,818
Ezetimibe74$1,516
Bumetanide21$1,495
Nitroglycerin59$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$13$12,49413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →